Holista Colltech Limited (HCT) AI Stock Analysis

• Market Cap: AU$25.75M
• Dividend Yield: N/A
• Average Volume (3M): 72.05K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.07
• Revenue Growth: 6.76%
• EPS Growth: N/A
• Country: AU
• Employees: 3
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Packaged Foods
• EPS (TTM): >-0.01
• Shares Outstanding: 367,834,350
• 10 Day Avg. Volume: 123,924
• 30 Day Avg. Volume: 72,050
• PEG Ratio: -0.04
• Price to Book (P/B): 28.04
• Price to Sales (P/S): 5.45
• P/FCF Ratio: -20.61
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: AU$0.07 ▼(-25.56% Downside)
• Action: Reiterated Date: 03/01/26
• Date: Action: Reiterated 03/01/26

The score is driven primarily by weak financial performance (revenue deterioration, ongoing losses, and persistent negative operating/free cash flow with worsening cash burn) and bearish technical signals (below key moving averages with negative MACD). Valuation provides limited offset because the company is loss-making (negative P/E) and no dividend yield is available.

Positive Factors

Balance Sheet Improvement

Equity turning positive in 2025 indicates a repaired capital base versus prior years, lowering insolvency risk and improving the firm's structural ability to raise funds or absorb losses. This enhances counterparties’ confidence and provides a firmer platform for medium-term recovery and partnerships.

Product/Technology Diversification

The company's dual focus on branded ingestible wellness products and collagen-derived technologies creates diversified revenue pathways (direct consumer and B2B ingredient/technology supply). This structural mix can stabilize revenues over time and allows cross-selling and licensing opportunities if execution and commercial agreements scale.

Gross Margin Recovery

An improved gross margin in 2025 signals progress on product mix or cost controls and suggests underlying unit economics are recovering. If sustained alongside revenue stabilization, higher gross margins provide a path to restore operating profitability and reduce reliance on external funding over the medium term.

Negative Factors

Negative Cash Generation

Persistent negative operating and free cash flow, worsening in 2025, creates ongoing cash burn and financing dependency. Structurally weak cash generation limits ability to fund operations, invests in growth, or withstand shocks without dilutive or costly external financing, posing medium-term solvency and execution risks.

Sharp Revenue Contraction

A dramatic revenue decline in 2025 undermines scale economics and the viability of existing commercial channels. Structural revenue deterioration makes it harder to absorb fixed costs, weakens negotiating leverage with partners, and increases the time and investment required to return to sustainable profitability.

Elevated Leverage

High reported debt relative to modest equity amplifies financial risk and restricts flexibility. Elevated leverage increases interest and covenant pressure, limits capacity for strategic investments, and makes the company vulnerable to further revenue or margin shocks absent clear deleveraging or earnings improvement.

Holista Colltech Limited Business Overview & Revenue Model

Company Description

Holista CollTech Limited operates as a biotech company in Australia, Malaysia, and the United States. The company operates through Supplements, Ovine Collagen, Infection control Solutions, and Food Ingredients segments. It manufactures and wholesales dietary supplements; cosmetic grade collagen; and healthy food ingredients, including low-glycaemic index (GI) flour mix for noodles, pasta, flatbreads and other baked products, low-sodium salt, low-fat fried foods, less-calorie sugar, and low-GI sugar. The company also provides infection control solutions. Holista CollTech Limited is based in Subiaco, Australia.

How the Company Makes Money

Holista Colltech Limited generates revenue through multiple streams, primarily by selling its proprietary health and wellness products to consumers and businesses. The company has established key partnerships with distributors and retailers, enabling it to reach a broader market for its products. Additionally, HCT engages in contract manufacturing for third-party brands, which provides another significant source of income. The increasing global demand for natural and plant-based health solutions further contributes to the company's revenue, as it aligns with consumer trends towards healthier lifestyles.

Holista Colltech Limited Financial Statement Overview

Summary

Financials indicate significant strain: sharp revenue contraction, negative operating profit and weaker net margins, and consistently negative operating/free cash flow (worsening in 2025). Balance sheet equity turned positive in 2025, but leverage remains high versus equity and profitability pressure persists.

Income Statement

Performance remains weak and inconsistent. Revenue has contracted sharply in the latest period (2025: -106% growth vs 2024: -5.9%), and profitability has deteriorated: 2025 shows negative operating profit and a -16.5% net margin versus near-breakeven net losses in 2024 (-1.5% net margin). Gross margin improved versus 2024 (13.4% vs 1.6%), but it is still far below earlier levels (2022: ~51.5%), highlighting volatility in the core economics and limited earnings quality.

Balance Sheet

Leverage is elevated and the capital structure has been unstable. While equity returned to positive in 2025 (~1.12M) after being negative in 2023–2024, debt remains significant (~1.59M) and the debt-to-equity level is high (2025: ~1.42x). The company has also shown large swings in returns on equity, including deeply negative levels in 2025, signaling ongoing pressure on shareholder value despite the balance sheet improvement versus the prior two years.

Cash Flow

Cash generation is a key weakness: operating cash flow is negative across all years shown, including 2025 (-1.35M) and 2024 (-1.01M), and free cash flow is also consistently negative (2025: -1.52M). Free cash flow deterioration in 2025 is severe (growth: -33.85), implying worsening cash burn and ongoing funding risk unless profitability and working capital dynamics improve materially.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	5.76M	5.60M	5.95M	8.24M	8.02M
Gross Profit	770.25K	87.03K	370.06K	4.24M	1.31M
EBITDA	-788.46K	304.37K	-4.52M	-1.02M	-957.40K
Net Income	-948.92K	-84.21K	-4.81M	-1.45M	-1.26M
Balance Sheet
Total Assets	5.87M	3.34M	3.35M	5.52M	6.93M
Cash, Cash Equivalents and Short-Term Investments	2.16M	21.72K	59.77K	117.53K	1.21M
Total Debt	1.59M	1.77M	1.57M	1.22M	890.32K
Total Liabilities	6.29M	6.71M	6.74M	3.96M	3.95M
Stockholders Equity	1.12M	-1.73M	-1.97M	2.83M	4.10M
Cash Flow
Free Cash Flow	-1.52M	-1.02M	-411.67K	-1.19M	-1.72M
Operating Cash Flow	-1.35M	-1.01M	-407.12K	-1.11M	-1.68M
Investing Cash Flow	-176.36K	692.12K	-46.70K	-105.69K	50.35K
Financing Cash Flow	3.65M	143.75K	418.42K	120.85K	109.49K

Holista Colltech Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.09
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HCT, the sentiment is Negative. The current price of 0.09 is above the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.08, and above the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 18.11 is Positive, neither overbought nor oversold. The STOCH value of 5.40 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:HCT.

Holista Colltech Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
MBH	54 Neutral	AU$37.18M	-2.03	-31.14%	―	-15.07%	29.45%
WNX	42 Neutral	AU$6.72M	-0.35	-184.71%	―	39.53%	49.99%
OMG	42 Neutral	AU$7.57M	-3.85	-77.48%	―	63.30%	70.00%
HCT	41 Neutral	AU$25.75M	-26.92	―	―	6.76%	―
EVE	41 Neutral	AU$5.70M	-2.33	-60.84%	―	-18.70%	20.83%

Holista Colltech Limited Corporate Events

Holista Colltech lifts revenue and margins but one-off legal costs drive FY2025 loss

Holista Colltech reported a 3% rise in full-year 2025 revenue to about $5.8 million, driven mainly by an 11.4% increase in dietary supplements sales and favourable foreign exchange movements, despite a sharp fall in food ingredients revenue. Gross margin improved to 45% from 42% on pricing discipline and cost controls, but the group still posted a pre-tax loss of $909,000 as one-off legal costs tied to an ASIC penalty and the ProImmune dispute outweighed debt recoveries.

The company’s Malaysian operations delivered a profit before tax of $889,000 including one-off debt recoveries, or $152,000 on an underlying basis after expense rationalisation and tighter cost management. Management highlighted ongoing cost-cutting and efficiency initiatives to support financial sustainability in a challenging demand environment, underscoring a strategic shift toward higher-margin supplements while food ingredients remain under pressure.

Holista said all figures remain subject to audit but signalled that currency gains, selective pricing and disciplined spending are central to stabilising earnings. The results suggest the group is relying on operational efficiencies and its growing supplements segment to offset legal overhangs and weakness in other product lines, with implications for its future capital allocation and market positioning.

The most recent analyst rating on (AU:HCT) stock is a Sell with a A$0.08 price target. To see the full list of analyst forecasts on Holista Colltech Limited stock, see the AU:HCT Stock Forecast page.

Holista Colltech Delivers Positive Cash Flow and Strong Liquidity Amid Softer Market

Holista Colltech reported a return to positive operating cash flow in the December 2025 quarter, delivering a net operating cash inflow of $238,000 supported by a 26.8% quarter-on-quarter reduction in operating costs to $1.46 million, despite one-off legal expenses. Group sales totaled $1.15 million, with headline figures impacted by a one-off accounting adjustment; underlying sales fell about 11.8% in line with broader market softness, while the core dietary supplements division showed resilience with only a modest underlying quarterly decline and year-on-year growth. Liquidity remained robust with $2.2 million in cash and $1.3 million in undrawn credit facilities, supplemented by $1.7 million in customer receipts, improved debt recovery and a $2.3 million capital raising, collectively strengthening the balance sheet and providing a meaningful buffer as the company continues to prioritize cost discipline in challenging market conditions.

The most recent analyst rating on (AU:HCT) stock is a Sell with a A$0.08 price target. To see the full list of analyst forecasts on Holista Colltech Limited stock, see the AU:HCT Stock Forecast page.

Holista Colltech Faces $1.09 Million Legal Cost Claim from ASIC

Holista Colltech Limited has received a notice from the Australian Securities and Investments Commission (ASIC) seeking recovery of legal costs amounting to approximately $1.09 million following Federal Court proceedings. The company is currently reviewing the notice and evaluating its options regarding the claim, with further updates to be provided as necessary. This development may impact Holista’s financial obligations and necessitates careful consideration of its legal and operational strategies.

The most recent analyst rating on (AU:HCT) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Holista Colltech Limited stock, see the AU:HCT Stock Forecast page.